News

Eris Lifesciences has drawn down a working capital term loan amounting to Rs 64.40 crore from Axis Bank to meet other short-term liabilities. The aggregate debt level of the company would, therefore, remain unchanged.

Net profit of ERIS Lifesciences rose 20.68% to Rs 142.39 crore in the quarter ended June 2026 as against Rs 117.99 crore during the previous quarter ended June 2025. Sales rose 12.63% to Rs 869.03 crore in the quarter ended June 2026 as against Rs 771.56 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales869.03771.56 13 OPM %34.0435.86 - PBDT251.56231.61 9 PBT179.49161.10 11 NP142.39117.99 21 Powered by Capital Market - Live News

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 29 July 2026.

Net profit of ERIS Lifesciences rose 200.10% to Rs 281.61 crore in the quarter ended March 2026 as against Rs 93.84 crore during the previous quarter ended March 2025. Sales rose 7.07% to Rs 752.29 crore in the quarter ended March 2026 as against Rs 702.60 crore during the previous quarter ended March 2025.For the full year,net profit rose 76.08% to Rs 619.52 crore in the year ended March 2026 as against Rs 351.84 crore during the previous year ended March 2025. Sales rose 8.18% to Rs 3114.89 crore in the year ended March 2026 as against Rs 2879.26 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales752.29702.60 7 3114.892879.26 8 OPM %36.2135.92 -35.9635.33 - PBDT228.98206.12 11 935.28804.33 16 PBT159.41128.87 24 655.78488.87 34 NP281.6193.84 200 619.52351.84 76 Powered by Capital Market - Live News

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 20 May 2026, inter alia, have recommended the interim dividend of Rs 7.21 per equity Share (i.e. 721%) , subject to the approval of the shareholders.